false
OasisLMS
ar,zh-CN,zh-TW,en,fr,de,hi,it,ja,es,ur
Login
Catalog
SCAI 2026 Workshop on the Treatment of Pulmonary E ...
Panel Discussion 3
Panel Discussion 3
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The discussion focused on pulmonary embolism (PE) trials, risk stratification, and follow-up care. Speakers compared upcoming studies and suggested HiPITE may be the most “positive” trial because it uses a highly enriched population and a sensitive definition of clinical deterioration. PEERLESS2 may overcome less sensitive endpoints by using a larger sample, while P-TRACT is broader and more hypothesis-generating.<br /><br />The panel emphasized the need to ask better research questions: Are current data elements sufficient? Should PE-specific risk scores be developed instead of using generic tools like NEWS? They also highlighted the importance of functional outcomes, quality-of-life measures, lactate, hemodynamics, and possibly AI/CT perfusion in future studies.<br /><br />A major takeaway was the need for specialized long-term follow-up of PE patients, similar to post-MI care.
Asset Caption
closed captions are computer-generated
Keywords
pulmonary embolism
risk stratification
clinical trials
follow-up care
quality of life
×
Please select your language
1
English